US Patent

US12291508 — Hydrazide containing nuclear transport modulators and uses thereof

Method of Use · Assigned to Karyopharm Therapeutics Inc · Expires 2032-07-26 · 6y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a compound represented by structural formula I and its uses, including as a CRM1 inhibitor.

USPTO Abstract

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I. or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2584 —
U-2584 —
U-3018 —
U-2584 —
U-3018 —
U-3018 —

Patent Metadata

Patent number
US12291508
Jurisdiction
US
Classification
Method of Use
Expires
2032-07-26
Drug substance claim
No
Drug product claim
No
Assignee
Karyopharm Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.